8-K/AOther Events

REGENERON PHARMACEUTICALS, INC. 8-K/A Report (Jan 26, 2001)

Filed January 26, 2001For Securities:REGN

Summary

This filing is an amendment to a previous 8-K report for Regeneron Pharmaceuticals, Inc. (REGN), dated January 25, 2001. The primary purpose of this amendment is to correct a minor typographical error in a press release that was originally issued earlier on the same day. The revised press release, dated January 25, 2001, is attached as Exhibit 99.1 to this filing. For investors, this is a very minor administrative update. It does not introduce new material information regarding the company's financial performance, operations, strategic initiatives, or significant business events. The correction is purely textual and does not alter the substance of the original announcement. Investors should refer to the original 8-K filing or subsequent reports for substantive business updates.

Key Highlights

  • 1Amendment to a previously filed 8-K report by Regeneron Pharmaceuticals, Inc.
  • 2The amendment corrects a minor typographical error in a press release issued on January 25, 2001.
  • 3A revised press release, dated January 25, 2001, is attached as Exhibit 99.1.
  • 4The event date for the earliest event reported is January 25, 2001.
  • 5This filing is an administrative correction and does not contain new material financial or operational information.
  • 6The company's principal executive offices are located at 777 Old Saw Mill River Rd, Tarrytown NY.

Frequently Asked Questions

This 8-K/A filing is an amendment to correct a minor typographical error found in a press release that Regeneron Pharmaceuticals, Inc. issued earlier on January 25, 2001. A revised version of the press release is included.

No, this filing is purely an administrative correction of a typographical error. It does not introduce any new material information related to the company's financial performance, strategic plans, or significant operational developments.

The corrected press release, dated January 25, 2001, is attached as Exhibit 99.1 to this 8-K/A filing.

Given that this is a minor correction of a typographical error and does not contain new material information, it is highly unlikely to have any significant impact on Regeneron's stock price. Investors should focus on substantive announcements for potential market-moving news.